Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.83 |
| ▸ | CTSD | P07339 | 2/20 | 0.83 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17815396 | 0.98 | BACE1 (0.83) | BACE1CTSDBACE2CYP2D6 | |
| SCHEMBL18707784 | 0.91 | BACE1 (1.00) | BACE1CTSDBACE2 | |
| SCHEMBL16040186 | 0.91 | BACE1 (1.00) | BACE1CTSDBACE2 | |
| SCHEMBL18707696 | 0.91 | BACE1 (1.00) | BACE1CTSDBACE2 | |
| SCHEMBL16041476 | 0.91 | BACE1 (1.00) | BACE1CTSDBACE2 | |
| SCHEMBL16041479 | 0.91 | BACE1 (1.00) | BACE1CTSDBACE2 | |
| SCHEMBL18707780 | 0.91 | BACE1 (1.00) | BACE1CTSDBACE2 | |
| SCHEMBL16040184 | 0.91 | BACE1 (1.00) | BACE1CTSDBACE2 | |
| SCHEMBL17815346 | 0.88 | BACE1 (0.82) | BACE1CTSDBACE2 | |
| SCHEMBL17815393 | 0.87 | BACE1 (0.82) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2511268-B2 | OXAZINE DERIVATIVE | SHIONOGI & CO (JP) | 2021-02-17 | — | — | EP | disclosed |
| US-9656974-B2 | Oxazine derivatives | SHIONOGI & CO., LTD. (JP) | 2017-05-23 | — | — | US | disclosed |
| US-20160159757-A1 | OXAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159757-A1 | OXAZINE DERIVATIVES | APP, BACE1, PSEN1 | BACE1 2/4885CTSD 3904/4885BACE2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.